Никита Михайлович Волков
Institute of Oncology NN Petrov · 96 works · 983 citations · h-index 11
Top works
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- Effect of silver oxide nanoparticles on tumor growth in vivo
- Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- Tumor acidity: From hallmark of cancer to target of treatment
- Professional Burnout in European Young Oncologists: a European Survey Conducted By the European Society for Medical Oncology (Esmo) Young Oncologists Committee
- Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
- Tumor alkalization therapy: misconception or good therapeutics perspective? – the case of malignant ascites
- Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion
- Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression
- Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer
- Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
- Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants
- Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
- EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts
- High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation
- MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS
- Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
- Real world efficacy of immunotherapy in nonsmall cell lung cancer
- Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome
- First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients